Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewLink Genetics has received a notice of allowance for a Japanese patent entitled, Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase.
Subscribe to our email newsletter
The patent contains pharmaceutical composition claims covering NewLink’s HyperAcute products for the treatment of cancer.
NewLink holds exclusive rights to the allowed application as well as to previously issued counterpart patents in the US, Canada, Mexico, and Europe.
NewLink Chairman and CEO Charles Link said: "These patents are valuable additions to our intellectual property portfolio in the immunotherapy arena."